The British Artificial Nutrition Survey 2001 recorded 507 home parenteral nutrition (HPN) patients (Crohn's disease 31·5 %, vascular disease 19·7 %, cancer 6·9 %). Parenteral nutrition was administered via tunnelled central line (92 %) and supplied by a commercial homecare company in 89 % of cases. The majority of HPN patients live at home (95·5 %) with an independent life (74 %), normal activity (59·2 %) and 92 % survive 1 year. However, there is good evidence that the geographical distribution of HPN patients is uneven (prevalence no patients to thirty-six patients per million of the population) suggesting inequity of access. Patients are increasingly concerned about the distances travelled to main centres and variable standards of more local support. Funding issues continue to cause difficulties as commissioning of health care transfers from Health Authorities to Primary Care Trusts. The two nationally-funded intestinal failure units provide HPN services to 220 HPN patients. HPN-related readmissions have displaced those awaiting admission for intestinal failure treatment, for which the waiting list mortality in one unit has risen to 14 %. The government has now recognised HPN as a specialised service distinct from intestinal failure and that existing medium-sized HPN units should be encouraged to take on HPN patients from intestinal failure units and smaller units. In Scotland a Managed Clinical HPN Network supported by the Scottish administration now cares for seventy-two patients under common protocols. The challenge for the future is how to provide high-quality care to all who need it in the rest of the UK.
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Home parenteral nutrition: Intestinal failure
BANS, British Artificial Nutrition Survey; BAPEN, British Association for Parenteral and Enteral Nutrition; HPN, home parenteral nutrition; IFU, intestinal failure unit; NSCAG, National Specialised Commissioning Advisory Group.
Patients with intestinal failure require replacement therapy just as do patients with other organ failure. Medium-to long-term intestinal failure is most commonly a result of short bowel syndrome, although some patients have intact but non-functioning guts. Intravenous nutrition provided at home in a manner analogous to home haemodialysis now offers patients hope of prolonged and improved quality of life. As with many novel treatments, innovative and inspired clinical leadership has led to the provision of home parenteral nutrition (HPN) in many centres in the UK. To date, no centre has been officially recognised as a provider of HPN and there is no nationally-coordinated HPN service. Using data from the British Artificial Nutrition Survey (BANS; Elia et al. 1999 Elia et al. , 2002 ) the British Association for Parenteral and Enteral Nutrition (BAPEN), chaired by Professor Chris Pennington, recognised in 1999 that the delivery of HPN in the UK is associated with inequity of access and highly variable quality of care. The present review describes the basis for these concerns and the progress made towards rectifying them. Much of the data on HPN is derived from the annual surveys performed by the BANS, a constituent body within BAPEN. Both BAPEN and BANS are multidisciplinary organisations that include representation from patients (Patients on Intravenous and Nasogastric Nutrition Therapy).
Historical perspectives
The first patients discharged home on intravenous nutrition in the UK were at St Mark's Hospital, London DQG +RSH +RVSLWDO 6DOIRUG LQ $ FHQWUDO UHJLVWHU RI  VXFK SDWLHQWV EHJDQ WR EH NHSW DOPRVW LPPHGLDWHO\ LQ  6DOIRUG ,Q WKLV IXQFWLRQ ZDV WUDQVIHUUHG WR %$16  ZKLFK KDV FRQGXFWHG RQJRLQJ VXUYH\V RI +31 HYHU VLQFH  ,Q 6LU 'DYLG &XWKEHUWVRQ RSHQHG D IRXUEHG LQWHV  WLQDO IDLOXUH XQLW ,) Tait & Baxter, 2002) . Joint protocols (Baxter & Tait, 2002) have been developed, agreed and circulated to participating centres, some of which have only one patient. Remote hospitals are supported by visits from the coordinator and training of local staff. Catheter sepsis rates have shown a slight reduction. Harmonisation of delivery of nutrition bags, ancillary equipment, documentation, patient-held records and patient information are in progress and audit is active . It is envisaged that economies of scale may be achieved by negotiation with homecare companies. It is clear that this project has been ground breaking and sets the standards for the rest of the UK to follow. However, progress will not be possible without the commitment and involvement of government agencies.
Welsh Managed Clinical Network
As in Scotland, the presence of strong devolved government in Wales has led to support for HPN as a specialised service. An embryo network is now being formed with Cardiff, Swansea and Wrexham as the involved centres. They will continue to work in close cooperation with the national intestinal failure centres.
England
With its much higher population, centralised government and the major changes in funding arrangements since April 2002, it has proved difficult to move forward. The policy of 'shifting the balance of power' devolves decision making to Primary Care Trusts. Strategic Health Authorities are only just beginning to become effective and Primary Care Trust specialised service consortia have not yet acquired the expertise or capacity to deal with all the issues relating to specialised services. During this difficult period BAPEN and the two IFU have been in negotiation with the Department of Health and some progress has been made.
First, the Department of Health has now recognised the distinction between intestinal failure and HPN services. This recognition is enshrined in the Specialised Services Definition no. 12 (HPN; London Regional Specialised Commissioning Group, 2001), which sets out the basic requirements for an HPN service and states that intestinal failure is separately funded by NSCAG.
Second, the Department of Health have noted that the national IFU are unable to subserve their designated role because the service is blocked by large numbers of HPN patients no longer requiring type 2 intestinal failure services. Initially, it was thought that more national IFU would be commissioned, but this policy has now changed. The Department of Health is now keen to build up a 'subnational service for HPN using existing strengths in networks or 'hub and spoke' arrangements according to local needs' (E Jessup, personal communication). It has also been noted that existing units will not be able to take on patients from the two national IFU or from smaller lessviable centres without investment. This constraint particularly applies to specialist nurses.
The way is now clear for BAPEN and other interested parties to move forward in England. It is now possible to aim for effective organisational restructuring similar to that in Scotland.
A 'sub-national' home parenteral nutrition service
There are approximately twenty units capable of providing HPN in England. Assuming a national point prevalence of fourteen patients per million of the population (700 patients), that the two national IFU continue to care for about eighty HPN patients each, and that Scotland has seventy-two HPN patients and Wales forty, the remaining 428 could be distributed between a network of twenty centres. Some teaching hospitals could probably take thirty or more patients, whereas smaller District General hospitals could support fifteen to twenty patients each. All centres would require increased investment. If every centre received funding for one more nurse, the expenditure would be relatively modest by comparison with creating new IFU. Smaller units have demonstrated quality of care comparable with that provided in major centres (Ransford & Jones, 2000) . Other resource implications relating to availability of beds and clinicians able to provide such a service would need to be addressed. BAPEN has been invited by the Department of Health to set standards for HPN to enable Primary Care Trusts commissioners to take well-informed decisions about the priority needed for HPN and to assess whether they are purchasing a high-quality service. All potential HPN centres should now be approaching their commissioners to seek endorsement and funding of their service.
Conclusions
It is clear that there is inequity of access to HPN and that quality of care is not uniform or satisfactory in many parts of the UK, particularly in England. There is much enthusiasm amongst professional staff and patients for change. The model of care now developing in Scotland provides a benchmark against which to compare services elsewhere in the UK. The proposal to develop a 'subnational' service for HPN will benefit the national intestinal failure service and permit equity of access and improved quality of HPN care. The recent agreement by government to support and develop existing HPN centres provides a great opportunity to move forward. Much of this progress should be attributed to Professor Chris Pennington, whose death in May 2002 has deprived Scotland and BAPEN of an inspired leader.
